We are thrilled to announce the latest addition to the Thuja portfolio. Artica Therapeutics is dedicated to developing a pipeline of covalent small molecules to advance the treatment of autoimmune and inflammatory disorders. Covalent drugs bind irreversibly to their target by design and are thought to yield improved efficacy.
Michel Briejer, managing partner at Thuja says: “Artica’s team harbours top-notch expertise regarding covalent drug development, which is an important reason to invest in Artica. We are extremely happy to be able to support Artica’s mission to develop better treatments addressing unmet medical needs.”
Congratulations to Artica's founders Tjeerd Barf, Arwin Ridder and Ad IJzerman on the successful closing of this €12M Seed round.
We are delighted to be joined by esteemed partners Seroba, Biogeneration Ventures and InnovationQuarter, as we support Artica in its mission to transform the lives of individuals living with autoimmune and inflammatory disorders.
Read full press release.
Visit Artica’s website: https://www.artica-tx.com